Purchase this article with an account.
Katia Ruiz-Montenegro Villa, Natalia Agudelo, Bárbara Rubio, Laura Ca�ola, josefina A. mejias smith, Jorge Camargo Acuña, MAYTHÉ ESTEPHANÍA CAMINO QUEZADA, José Chauca, Raúl Alberto Zúñiga Iracheta, Carmen Maldonado, Juan Carlos Izquierdo; Ab Interno Canaloplasty after failed Trabeculectomy in uncontrolled Open-Angle Glaucoma. Invest. Ophthalmol. Vis. Sci. 2019;60(9):6629.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To introduce an alternative surgical treatment for the management of uncontrolled open-angle glaucoma after failed trabeculectomy and report the outcomes in a consecutive series of patients.
Single center, retrospective, non-comparative, interventional, case series.We reviewed 9 eyes of 7 patients with uncontrolled OAG who underwent Ab interno canaloplasty after failed trabeculectomy. Outcomes measures included intraocular pressure, glaucoma medication, visual acuity and number of visits in postoperative care.
In all patients ab interno canaloplasty after failed trabeculectomy was successfully done, a condition required to leading canulation and viscodilation of schlemm`s canal was that the ostium of the trabeculectomy had to be anterior to the trabecular meshwork. Preoperative mean IOP was 17±2.66 mmhg and postoperative mean IOP at 6 months was 12.2 ±1.66 mmhg. There was a total reduction of 29.3% of IOP at 6 months follow-up. Glaucoma medications reduced from 3.5 ±1.5 to 1.14±0.85.At final visit 60% of the patients with 1 glaucoma medication and 10% without glaucoma medication. Visual acuity remains stable at 6 months. Numbers of visits after surgery were 4±1 in 6 months leading the patient rapid reincorporation of daily normal activities.The only Complication was hyphema in 50% of the patients, that resolves 1 week later without reintervention.
In patients with uncontrolled OAG after failed trabeculectomy abic appears to be a safe and effective procedure. At 6 months follow-up reduction in IOP remain stable and reduction in glaucoma medications was significantly reduce.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only